Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Institute Of Human Genetics Munich, |
RCV000995518 | SCV001149726 | pathogenic | X-linked Alport syndrome | 2018-03-15 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV000681893 | SCV001531374 | pathogenic | not provided | 2023-11-27 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 9 of the COL4A5 gene. It does not directly change the encoded amino acid sequence of the COL4A5 protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with Alport syndrome (PMID: 24304881). This variant is also known as c.546+2_3insT. ClinVar contains an entry for this variant (Variation ID: 562420). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 9, but is expected to preserve the integrity of the reading-frame (PMID: 24304881). This variant disrupts the triple helix domain of COL4A5. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL4A5, missense variants at these glycine residues are significantly enriched in individuals with disease (PMID: 23720012, 27627812) compared to the general population (ExAC). For these reasons, this variant has been classified as Pathogenic. |
| Gharavi Laboratory, |
RCV000681893 | SCV000809372 | pathogenic | not provided | 2018-09-16 | no assertion criteria provided | research |